Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
## Overview\nSodium phosphate + sodium phosphate is an oral **inorganic salt combination** of monobasic and dibasic sodium phosphate used primarily as an **osmotic laxative / bowel cleansing agent**. It increases intraluminal osmotic load in the gastrointestinal tract, drawing water into the bowel and producing rapid catharsis and diarrhea to evacuate colonic contents before colonoscopy; liquid OTC products have also been marketed for relief of occasional constipation. Public labels identify approved prescription tablet products including **OsmoPrep** and **Visicol** for colon cleansing prior to colonoscopy, and OTC oral saline laxative liquids containing dibasic sodium phosphate plus monobasic sodium phosphate have also been marketed. A key safety issue for oral sodium phosphate bowel preparations is **acute phosphate nephropathy** and associated electrolyte and renal toxicity risk, especially in susceptible patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium phosphate + sodium phosphate.